HPK1 kinase knockdown mice demonstrate increased CD8+ T‐cell killing function and robust antitumor immune responses even in a cold tumor environment, making HPK1 a high‐priority target in immuno‐oncology.407, 408. This evidence concerns the gene CD8A and neoplasm.